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Summary. - In this study, a 178 amino acids long portion of the hepatitis C virus (HCV) core gene was 
cl once~ sequenced, expressed in F:.w:IIC'richia coli, and purified. The resulting antigen (C 178) w',as tested with 
human scra enzyme-linked immunosorbent assay (ELISA) in order to assess its ability to diagnose HCV. It 
was shown by ELISA that 92%, of the patients scra, diagnosed previously by a 3"1 generation enzyme 
immunoassay (EIA) as HCV-positivc, had antibodies against the C 178 antigen. This antigen gave no false 
positive results when tested with anti-HCY-ncgative sera. 
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Introduction 
HCV is the major causative agent of the non-A and non-B 
hepatitis. It has been first identified using molecular cloning 
techniques (Kao et al., 1989; Choo et al., 1989). IICV is a 
single-stranded positive-sense RNA virus classified within 
the family Flaviviridae. A hundred million individuals are 
estimated to be chronically infected with I ICY and this 
number increases every year (Murphy et al., 1996). Over 
80% of those exposed to llCV become chronically infected, 
and 20% of them develop cirrhosis, possibly leading to 
hepatoeellular carcinoma. There is no vaccine available tu 
prevent HCV (Urdea et al., 1997). As HCV infection can 
have such serious consequences and its treatment is rarely 
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Abbreviations: anti-HCV = antibodies to HCV; bDNJ\ = bran-
ched DNA; El/\ = enzyme immunoassay; ELISA = enzyme-
linked immunosorbent assay; HCV = hepatitis C virus; NS = non-
structural; PBS = phosphate-buffered saline; PI3ST = PBS with 
0.05% Tween 20; PCR = polymerase chain reaction; RT-
PCR = reverse transcription-PCR 
efficacious, the tests that can identity HCV-infected patients 
are crucial for addressing this potentially life-threatening 
viral disease. The main screening assays for detecting and 
confirming antibodies to HCV (anti-HCV) are EIA and 
radio-immunublot assay. Tests for I-ICY RNA including 
PCR-hased and branched DNA (bDNA) ones, are used for 
therapeutic monitoring and prognostics (Younossi and 
Mcllutchison. 1996; Urdea et al., 1997). A I" generation 
anti-I·TCV test (ElA-1) uses a single HCV recombinant 
antigen derived from the non-structural (NS) 4 gene 
designated CI 00-3. Only 80% of the patients with clinical 
und molecular evidence of HCV infection were positive for 
anti-HCV by this method (Kao et al., 1989; Nagayama et 
al., 1993). A 21111 generation anti-HCV EIA (EIA-2), 
developed in 1992, employes the HCV antigens from the 
core (C22) and NS3 (C33) genes in addition to the NS4-
derived (CI 00) antigen (Mimms et al., 1990). Introduction 
of new antigens led to a substantial improvement in 
sensitivity and specificity of this test. It allows the detection 
of 95°/., of individuals with molecular evidence of HCV 
(Kleinman et al., 1992; i\ach et al., 1991 ). A 3"1 generation 
anti-HCV Eli\ (EIA-3) was designed to further improve 
sensitivity and specificity of detection by adding more 
antigens. IL uses three recombinant antigens (C22, CI 00, 
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and NS5) derived from four different regions of the I ICY 
genome. It is more sensitive (97%) and slightly more specific 
than preceding assays (Barrera et lll., 1995; Uyttendaele et 
lll., 1994), and the improvement in this assay has been 
attributed to the reconfigure<l antigens already present in 
EIA-2 but not to the NS5 antigen (Gretch, 1997). 
Although serological diagnostic accuracy has greatly 
been improved, there arc still a large numberoffalsc positive 
reactions given by E!As for low risk populations such as 
blood donors (Gretch, 1997). It has also been reported that 
in many commercially available EIAs fusion polypeptides 
and synthetic oligopcptides are used as HCY antigens and 
these may exhibit non-specific reactions and reduce the 
sensitivity of the epitopes involved (Seki et lll., 1995). To 
improve the detection rate, identification and generation of 
new antigens are required. A considerable sequence variation 
among HCY genotypes and subtypes may contribute to the 
complicated picture of HCY diagnostics. It should be noted 
that since the virus core gene is the most conserved genome 
region, it can be used to detect all HCV subtypes by Eli\. 
The full length core protein is 191 amino acids long (Bukh 
et lll., 1994). Although it is the most conserved region of 
HCV open reading frame, there arc variations among 
different IICY genotypes. The C terminal end of the core 
protein is found to be highly hydrophobic and reported to 
be cleaved (aa 172-191) (Hijikata et lll., 1991). For this 
reason we have amplified and cloned the first 178 amino 
acids portion of the core gene. 
Presently, 1.5'% of the general population in Turkey is 
thought to be infected with l·ICY which corresponds to about 
1 million people (Heintges and Wands, 1997). Very recently, 
blood donor sera began to be tested by E!As. The 
predominant genotype of the virus for Turkey has also 
recently been identified as I b (E. Yildiz, unpublished 
results). From this point of view it was reasonable to develop 
an EIA using an antigen derived from a Turkish I ICY isolate. 
In this report we describe cloning, expression, sequencing 
and production of almost the entire I-ICY core protein of a 
Turkish HCY isolate of subtype lb as a protein tagged with 6 
histidines. The recombinant protein C 178, when used in 
ELISA, appeared to contain almost all epitopes of II CY capsid 
protein and to detect anti-core proteins antibodies specifically. 
Materials and Methods 
Reagents. All restriction cndonuclcascs and DNA modifying 
enzymes were purchased from MBI Fermentas. The Ni-NT/\ resin 
for purification of C 178 was purchased from Qiagcn. All other 
chemicals were from Sigma, Difeo, and Carlu-Erba. 
Bacterial strains and plasmids. E. coli strains .IM I 09 and M 15 
were used for construction and propagation of an expression 
plasmid and production of recombinant proteins. pQE30 expression 
plasmid (Qiagcn) was used for cloning and expression studies. 
RNA extrac:tio11 am/ re,•erse transcriptio11-PCR (RT-PCR). Total 
RNA was extracted from a chronic hepatitis C patient's serum by 
the single step guanidinium thiocyanate method (Wilson et al., 
1995) with slight modifications. Six hundred 111 of the scrum 
was mixed with 3 ml of a denaturing solution (4 11101/1 guanidi-
nium thiocyanate. 25 11111101/I sodium citrate pH 7.0, 0.1 mul/1 
2-mcrcaptoetlrnnol, and 0.5% N-laurylsareusine) and vortexed 
briclly. Then 300 1il of 2 11101/1 sodium acetate pH 4.0, 3 ml of 
water-saturated phenol. and 600 111 ofchlorofurm:isoamylalcuhul 
(49: I) was added and the mixture was vortexed. The mixture was 
then incubated on ice for 15 mins and centrifogcd at 12,000 rpm 
for 15 mins at 4"C. The aqueous phase was precipitated with one 
volume of I OO'X, isopropanol at -20"C fur 30 mins and centrifogcd 
at 12,000 rpm fur 20 mins al 4"C. The pellet was dissolved in 250 111 
of the denaturing solution and an equal volume of isopropanol was 
added. The mixture was incubated at -20"(' for 30 mins and 
centrifuged at 12,000 rpm for 20 mins at 4"C. The pellet was washed 
with 500 1t1 uf70'X, ethanol, centrifogcd, air-driecL and resuspended 
in IO 1il of dicthylpyrucarbunatc-trcatcd distilled water. 
The isolated RNA (IO 111) was reverse transcribed after 
incubation at 70"C fur 5 mins using a KJ:rcR kit (Stratagene) 
according to the producer's instructions. 
The obtained cDNA was amplified by PCR in a total volume 
of 50 111 containing I U of Pfi1 DNA polymerase (Stratagcnc), 
5 pl of the Pfit polymerase buffer, 200 1111101/1 dNTPs 
and 50 pmules of HCV cure gene-specific sense (5 · -
CGCGGATCCATGAGCACG/ AAATCCTAAACC-3' containing 
an unique TJamH1 site (in bold)) and anti-sense (5'-
CGCAAGCTTGAGGAJ\G1\TAGAG/AAAAGAGCAACC-3' 
containing an unique Him/Ill site (in bold)) primers. The PCR was 
performed in 30 cycles, each cycle consisting ofa dcnaturation step 
at 94"(' for I min. a primer annealing step al 55"C for 45 secs, and 
an extension step at 72"C fur I min. This was followed by a single 
cycle consisting of a final elongation step at 72"(' for 10 mins 
followed by cooling to 4"C. 
C/011i11g <~( t!te HCV core gene. After digestion with BamHI 
and lli11c/lJI, the PCR product encoding the HCV core gene was 
ligated with the corresponding sites in pQE30 vector and the 
obtained recombinant plasmid (pQECORE) was recovered 
following transformation of E. coli JM I 09. 
DNA seq11e11c:ing of the core gene in pQE vector was carried 
out on an ABT Prism 377 sequencer by Dr. B. Ccvhcr of the Bilkcnt 
University. 
Prod11ctio11 of reco111bina11/ c:ore antigen in E. c:oli and its 
p11r(ficatio11. The recombinant plasmid pQECORE was used tu 
transform£. coli !'vi 15 cells and single colonies were used tu induce 
high-level expression of the core protein. A small-scale induction 
for initial screening of protein expression was performed by 
inoculating 5 ml of L broth with 200 1il of an overnight culture 
that had been inoculated with a single colony. Fur large-scale 
induction, 30 ml of medium was inoculated with a single colony, 
grown overnight at 37"C. and this was then used to inoculate I I 
ufL broth at the same tcmpcran1rc. Protein expression was induced 
by addition of I 11111101/1 IPTG when the cells had reached A,,1111 of 
0.6-1.0. Incubation was continued for additional 1--5 hrs prior to 
harvesting the cells by centrifugation. Small-scale cultures were 
harvested by ccntri fugation at 12,000 rpm fur 2 mins in a bench lop 
microcentrifuge. Large-scale cultures ( 100-IOOO ml) were 
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Fig. I 
Results of expression, solubilizalion, purification and Western blot 
analysis or C 17!1 prolcin 
Protein size markers (94 K, 66 K, 43 K, 36 K, and 21 K, lane 1 ), induced 
insoluble fraction (lane 2), induced soluble fraclion (lane 3), lhc lane 2 
sample after solubilizalion (lane 4), lhc lane 3 sample atkr solubilizalion 
(lane 5), the affinity chromalography-purified C 178 pro1cin (lane 6), 1hc 
lane 6 sample reacted with human anti-C 178. 
harvested by centrifugation at 5000 rpm for IO mins at 4"C in a 
Beckman Jt\ rotor. Purification of the fraction of induced protein 
soluble in 8 mol/1 urea was carried out essentially as described in 
the Qiagen's Qiaexprcss manual. Concentration of the purified 
protein was determined according to Bradford ( 1976). 
Western blot 1111a~Fsis. After SDS-Pt\GE, the gel was blotted 
onto a polyvinylidcne dinuoride membrane (Sambrook et al., 
1989). The blot was incubated in 50 ~ti of a blocking solution ( I 0% 
skimmed milk, and 0.2% Tween 20 in phosphate-buffered saline 
(PBS) pH 7.4) overnight with continous shaking at 4"C and then 
washed with PBS containing 0.05%, Tween 20 (l'BST). It was then 
incubated in the blocking solution containing the primary antibody 
(a patient's serum, 1/200 dilution) for I hr and washed with Pl3ST 
for IO mins. The blot was treated with the secondary antibody (a 
T-IRP-conjugated anti-human antibody) for I hr in the blocking 
solution and the bands were visualized using the ECL kit 
(t\mcrsham) according to the producer's instructions. 
ELISA. The sern of the patients were screened by ELISA as 
described by Sambrook et al. ( 1989) with slight modification. The 
wells of microtiter plates (96 wells, Nunc) were coated overnight 
with 100 ng/well of the core antigen in PBS containing 0.02% 
NaN,. The coated plates were incubated first with 200 rtl/wcll of a 
blocking solution (5% skimmed milk and 0.02'X.NaN1 in PBS 
pH 7.4) for I hr and then with the blocking solution containing a 
scrum (diluted I :200) for another hr and washed with PBST 3 times 
after each of these steps. A blrn.:king solution rnntaining alkaline 
phosphatase-conjugated antibodies (Sigma) (diluted I :30,000) 
against human JgG, Mandt\ was then added (200 rd/well). After 
I hr at room temperature, the unbound conjugate was removed by 
3 washings with Pl3ST and 200 111/well of a substrate solution 
containing I mg/ml PNPP was added . The amount of substrate 
hydrolyzed was assessed by a 13iomek 2000 Automated Laboratory 
Workstation (Beckman), by reading t\., ... after incubation in dark 
for 1-2 hrs at room temperature. 
Results 
Production ofreco111hina11t core antigen (CJ 78) 
in £. coli and it.Y pur(fkation 
In order to optimize the expression conditions we 
examined the influence of growth temperature, induction 
time and IPTG concentration upon C 178 protein expression. 
We found that optimum IPTG concentration was I mmol/1, 
induction time 3 hrs, and induction temperature 37"C 
(Fig. I) It should be noted that inducing of the cells at lower 
temperatures (30"C or 25"C) dramatically decreased the 
expression level. At the optimal temperature almost all of 
the expressed protein was in the insoluble portion. Almost 
60% of it was solubilized with 8 mol/1 urea. The protein 
purified by affinity chromatography was more than 90% 
pure as determined by SOS-PAGE. 
CJ 78 protein-based £USA .fh,)mti-HCV 
The purified C 178 was used in ELISA. The specificity 
of the C 178 protein in ELISA was determined by testing 
100 HCV EIA-posilive (exclusively la and lb subtypes) 
and 60 EIA-negativc sera as determined by a 3,t1 generation 
EIA. For comparison, also RT-PCR was performed to detect 
HCY RNA in the tested sera . The results are shown in 
Table I . A negative control serum was previously tested and 
found HCV RNA-negative by RT-PCR and anti-HCY-
negative by Western blot analysis. ELISA readings at least 
2 .5 times higher than that of the negative control were 
regarded as positive, while those at most 1.5 times lower 
than that of the negative control were regarded as negative. 
No ELISA readings between 1.5-fold and 2.5-fold of that 
of the negative control were obtained. Of JOO E!A-positive 
sera 89 were positive and 11 were negative in ELISA. All 
the 60 El A-negative sera were also ELISA-negative. In order 
to further test lhc 11 El A-positive and ELISA-negative sera 
we performed Western blot analysis using the C 178 protein 
as a probe antigen (data not shown). We could not detect 
Table I. Results of anli-HCV assays b~· EIA and ELISA and IICV 




/\nl i-HCV-ncgalivc·' 60 
"l)ctcrmincd by a 3"' generation El/\. 





No. of scra 
RT-l'CR 
+ 
11 97 3 
60 0 60 
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any reaction for 3 of these sera. These sera were found HCV 
RNA-negative in RT-PCR suggesting that they were false 
ETA-positive. The remaining 8 sern were found Western blot-
positive and RT-PCR-positive. 
In conclusion, 92% of the patients, which were anti-HCV-
positive by ETA, were anti-HCV-positive also by ELISA 
using the C 178 antigen. This antigen showed no false 
positive results with the negative control sern suggesting 
that it interacted specifically with anti-HCV 
Discussion 
In this study, the 3 · -truncated con: gene of HCV was 
cloned and expressed and its product was purified and used 
in testing of human sera in order to assess its ability to 
diagnose HCV infection. Since the sequence of this gene 
varies among genotypes, we have first aligned the available 
GenBank HCY core gene entries and designed the primer 
pair to amplify the 178 amino acids long region of the core 
gene. This region showed variation. Moreover, the 
C-tcrminal end of the core protein (aa 172-191) is highly 
hydrophobic and reported to be cleaved which suggests that 
its first 171 amino acids contain important domains and 
possibly all of the immunodominant epitopes (Hijikata et 
al., 1991 ). Thus were concluded that the 178 amino acids 
long core antigen is comparable to the complete one as a 
probe in detecting antibodies raised by host against the HCV 
core. The amplified core protein (C 178) was cloned into 
bacterial expression plasmid pQE30, expressed in£. coli 
as an N-terminal his-tagged fusion protein, and purified by 
Ni ion affinity chromatography under denaturing conditions. 
The 6-His affinity tag not only enabled to purify the 
expressed protein by affinity chromatography but also to 
minimize addition of extra amino acids to the C 17 8 protein. 
To date, all core region antigens used in detecting HCV 
infection have either big polypeptides or small synthetic 
oligopeptides fused at their N-terminus. These fused 
(attached) polypeptides may exhibit non-specific reactions 
and reduce the reaction sensitivity of epitope(s). The core 
protein has been previously expressed in different organisms 
including insects, yeast, E. coli and mammalian cells and 
found to be useful for early diagnosis of HCV infection 
(Chiba et al., 1991; Harada et al., 1991; Chien et al., 1992; 
Yokosuka et al., 1993). However, in these studies, the 
expressed core antigen was not much purified or did not 
cover as large as 178 amino acids long portion of the core 
protein. The largest core protein that was expressed and 
purified to homogeneity (CI 15) contained its first 115 amino 
acids (Seki et al., 1995). 
We used the purified His-tagged C 178 in establishing an 
ELISA for detection of antibodies against HCV core protein 
in human scra. Eighty-nine of the 100 chronic hepatitis 
patients, that were previously tested by a 3"1 generation ElA 
and found positive, were found positive also in this ELISA, 
while 60 healthy (control) subjects were negative both in 
EIA and ELISA. The cut off value for a positive resul was 
chosen at the 2.5-fold of the average of the negative control 
readings. The limit for a negative result was chosen at the 
I .5-fold of that average. There were no readings between 
these two limits, however, in the future, samples with such 
readings should be retested, and if these results would be 
confirmed, another method such as Western blot analysis 
should be used. In order to decide whether our 11 ELISA-
negative sera were due to insensitivity of our ELISA or lack 
of antibodies against C 178, we subjected them to Western 
blot analysis and RT-PCR. Eight of these sera were positive 
in both tests. Three EIA-positive sera were negative in both 
ELISA and RT-PCR, which suggested that they were false 
EIA-positivc. Therefore it can be concluded that the 
sensitivity of our ELISA was 92% (89/97) compared to ETA. 
As C 178 was produced in E. coli, there might he some 
impurities in the protein preparation and these could interact 
with the sera and give false positive results. In order to 
eliminate this possibility, an£. coli lysate was prepared and 
used as an internal control in ELISA. We found that it did 
not interact with the sera. 
There are I'', 21111 and 3"1 generation EIAs used worldwide 
for the diagnosis ofHCV infection. The sensitivity of these 
assays ranges from 80%, to 97%. When compared to them, 
the sensitivity of our ELISA is between the 2"'1 and 3"1 
generation EIAs. These EIAs use antigens from the core 
region as well as NS3, NS4 and NS5 regions. The core 
protein is the putative capsid protein of HCV and antibodies 
directed to the viral capsicl proteins arc expected to arise 
early in infection. Therefore, antibodies against the core 
protein most probably arise much earlier than those against 
the non-structural proteins. That is why it is important to 
include all of the epitopes of the core region into the probe 
antigen used in an EIA to increase its efficiency. We believe 
that CI 78 protein contains all the epitopes of the core region 
oflTCV 
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